Memorial Hospital Research Laboratories
The Nai-Kong Cheung Lab
Research
Professor
My lab focuses on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.
Featured News
Publications Highlights
Yankelevich M, Thakur A, Modak S, Chu R, Taub J, Martin A, Schalk DL, Schienshang A, Whitaker S, Rea K, Lee DW, Liu Q, Shields A, Cheung NK, Lum LG. Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells. J Immunother Cancer. 2024 Mar 21;12(3):e008744. doi: 10.1136/jitc-2023-008744
Kramer K, Pandit-Taskar N, Kushner BH, Zanzonico P, Humm JL, Tomlinson U, Donzelli M, Wolden SL, Haque S, Dunkel I, Souweidane MM, Greenfield JP, Tickoo S, Lewis JS, Lyashchenko SK, Carrasquillo JA, Chu B, Horan C, Larson SM, Cheung NV, Modak S. Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies. J Hematol Oncol. 2022 Nov 12;15(1):165. doi: 10.1186/s13045-022-01383-4.
Park JA and Cheung NK. Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies. J Immunother Cancer. 2022 Jan;10(1):e003771. doi: 10.1136/jitc-2021-003771.
Hoseini SS, Vadlamudi M, Espinosa-Cotton M, Tran H, Feng Y, Guo HF, Xu H, Cheung I, Cheung NK. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. J Immunother Cancer. 2021, May;9(5):e002509. doi: 10.1136/jitc-2021-002509.
Xu H, Buhtoiarov IN, Guo HF, Cheung NK. A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy. Oncoimmunology. 2021 Mar; 10(1):1893500. doi: 10.1080/2162402X.2021.1893500.
People
Nai-Kong V. Cheung, MD, PhD
Enid A. Haupt Chair in Pediatric Oncology, Pediatrics
Professor
- Physician-scientist Nai-Kong Cheung focuses on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.
- MD, PhD (Immunology), Harvard Medical School
- [email protected]
- Email Address
- 646-888-2313
- Office Phone
- View physician profile
- Physician profile
Members
Lab Alumni
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Career Opportunities
Get in Touch
-
Lab Head Email
-
Office Phone
-
Lab Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Nai-Kong V. Cheung discloses the following relationships and financial interests:
-
Abpro Inc
Equity; Intellectual Property Rights -
Biotec Pharmacon
Intellectual Property Rights
-
Eureka Therapeutics Inc
Equity -
Y-mAbs Therapeutics, Inc.
Equity; Intellectual Property Rights
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].